Lymphomas with an activating mutation in the catalytic SET domain of EZH2 are strongly affected by treatment with the EZH2 inhibitor GSK126 [9] and clinical trials with EZH2 inhibitors are currently ongoing. The gene discussed is EZH2; the disease is lymphoma.